Belite Bio, Inc
BLTE
Rank in Stocks
#2968
Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the... Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapies. The firm's primary therapeutic areas include atrophic age-related macular degeneration and autosomal recessive Stargardt disease. Its flagship drug candidate, LBS-008, is an investigational oral medication administered once daily. Currently undergoing Phase 3 clinical trials, LBS-008 is engineered to modulate vitamin A delivery to the eye, thus preventing the accumulation of detrimental vitamin A metabolites in ocular tissues. Furthermore, Belite Bio is advancing LBS-009, an oral anti-retinol binding protein 4 therapy, through preclinical development. This therapy targets various liver ailments, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Founded in 2016, Belite Bio, Inc. is headquartered in San Diego, California, and operates as a subsidiary of Lin Bioscience International Ltd.
Share Price
$154.77
Market Cap
$6.23B
Change (1 day)
5.04%
Change (1 year)
71.26%
Country
US
Trade Belite Bio, Inc (BLTE)
Category
Healthcare
P/B ratio for Belite Bio, Inc (BLTE)
P/B ratio as of October 2026 TTM: 7.90
According to Belite Bio, Inc latest financial reports and stock price the company's current price-to-book ratio (TTM) is 7.90. At the end of 2023 the company had a P/B ratio of 13.45.
P/B ratio history for Belite Bio, Inc from 2020 to 2026
P/B ratio at the end of each year
| Year | P/B Ratio | Change |
|---|---|---|
| 2026 (TTM) | 7.90 | -40.18% |
| 2024 | 13.21 | -1.78% |
| 2023 | 13.45 | -7.28% |
| 2022 | 14.51 | -185.83% |
| 2021 | -16.91 | 22.03% |
| 2020 | -13.85 | 0.00% |
P/B ratio for similar companies or competitors
| Company | P/B Ratio | P/B Ratio Difference | Country |
|---|---|---|---|
| 6.251 | -20.89% |
US
|
|
| 13.2547 | 67.75% |
US
|
|
| 4.208 | -46.74% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | -21.76% |
NL
|
